Krüppel-like Factor 5 Contributes to Pulmonary Artery Smooth Muscle Proliferation and Resistance to Apoptosis in Human Pulmonary Arterial Hypertension

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2011 Sep 29

PMID 21951574

Citations 54

Authors

Audrey Courboulin

Veronique L Tremblay

Marjorie Barrier

Jolyane Meloche

Maria Helena Jacob

Mathilde Chapolard

Malik Bisserier

Roxane Paulin

Caroline Lambert

Steeve Provencher

Sebastien Bonnet

Affiliations

Soon will be listed here.

Abstract

Background: Pulmonary arterial hypertension (PAH) is a vascular remodeling disease characterized by enhanced proliferation of pulmonary artery smooth muscle cell (PASMC) and suppressed apoptosis. This phenotype has been associated with the upregulation of the oncoprotein survivin promoting mitochondrial membrane potential hyperpolarization (decreasing apoptosis) and the upregulation of growth factor and cytokines like PDGF, IL-6 and vasoactive agent like endothelin-1 (ET-1) promoting PASMC proliferation. Krüppel-like factor 5 (KLF5), is a zinc-finger-type transcription factor implicated in the regulation of cell differentiation, proliferation, migration and apoptosis. Recent studies have demonstrated the implication of KLF5 in tissue remodeling in cardiovascular diseases, such as atherosclerosis, restenosis, and cardiac hypertrophy. Nonetheless, the implication of KLF5 in pulmonary arterial hypertension (PAH) remains unknown. We hypothesized that KLF5 up-regulation in PAH triggers PASMC proliferation and resistance to apoptosis.

Methods And Results: We showed that KFL5 is upregulated in both human lung biopsies and cultured human PASMC isolated from distal pulmonary arteries from PAH patients compared to controls. Using stimulation experiments, we demonstrated that PDGF, ET-1 and IL-6 trigger KLF-5 activation in control PASMC to a level similar to the one seen in PAH-PASMC. Inhibition of the STAT3 pathway abrogates KLF5 activation in PAH-PASMC. Once activated, KLF5 promotes cyclin B1 upregulation and promotes PASMC proliferation and triggers survivin expression hyperpolarizing mitochondria membrane potential decreasing PASMC ability to undergo apoptosis.

Conclusion: We demonstrated for the first time that KLF5 is activated in human PAH and implicated in the pro-proliferative and anti-apoptotic phenotype that characterize PAH-PASMC. We believe that our findings will open new avenues of investigation on the role of KLF5 in PAH and might lead to the identification of new therapeutic targets.

Citing Articles

Pulmonary Hypertension: Molecular Mechanisms and Clinical Studies.

Adu-Amankwaah J, You Q, Liu X, Jiang J, Yang D, Liu K MedComm (2020). 2025; 6(3):e70134.

PMID: 40066229 PMC: 11892029. DOI: 10.1002/mco2.70134.

Peri-Operative Changes of Inflammatory Markers and Their Implications in Pulmonary Endarterectomy.

Liu Q, Zhao Z, Yang J, Cao Y, Zhang M Rev Cardiovasc Med. 2024; 23(11):357.

PMID: 39076189 PMC: 11269080. DOI: 10.31083/j.rcm2311357.

TAK1 in Vascular Signaling: "Friend or Foe"?.

Fan G, Lu J, Zha J, Guo W, Zhang Y, Liu Y J Inflamm Res. 2024; 17:3031-3041.

PMID: 38770174 PMC: 11104388. DOI: 10.2147/JIR.S458948.

Abnormal expression of Krüppel-like transcription factors and their potential values in lung cancer.

Shi Y, Yao M, Shen S, Wang L, Yao D Heliyon. 2024; 10(7):e28292.

PMID: 38560274 PMC: 10979174. DOI: 10.1016/j.heliyon.2024.e28292.

Causal effect of interleukin (IL)-6 on blood pressure and hypertension: A mendelian randomization study.

Wu O, Wu Y, Zhang X, Liu W, Zhang H, Khederzadeh S Immunogenetics. 2024; 76(2):123-135.

PMID: 38427105 DOI: 10.1007/s00251-024-01332-0.

References

Liu R, Zheng H, Zhou Z, Dong J, Chen C . KLF5 promotes breast cell survival partially through fibroblast growth factor-binding protein 1-pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization. J Biol Chem. 2009; 284(25):16791-16798. PMC: 2719315. DOI: 10.1074/jbc.M808919200. View

Ryan B, Konecny G, Kahlert S, Wang H, Untch M, Meng G . Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 2006; 17(4):597-604. DOI: 10.1093/annonc/mdj121. View

Yildiz P . Molecular mechanisms of pulmonary hypertension. Clin Chim Acta. 2009; 403(1-2):9-16. DOI: 10.1016/j.cca.2009.01.018. View

Cheng Y, Liu X, Yang J, Lin Y, Xu D, Lu Q . MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res. 2009; 105(2):158-66. PMC: 2728297. DOI: 10.1161/CIRCRESAHA.109.197517. View

He M, Han M, Zheng B, Shu Y, Wen J . Angiotensin II stimulates KLF5 phosphorylation and its interaction with c-Jun leading to suppression of p21 expression in vascular smooth muscle cells. J Biochem. 2009; 146(5):683-91. DOI: 10.1093/jb/mvp115. View

Yang Y, Goldstein B, Chao H, Katz J . KLF4 and KLF5 regulate proliferation, apoptosis and invasion in esophageal cancer cells. Cancer Biol Ther. 2005; 4(11):1216-21. DOI: 10.4161/cbt.4.11.2090. View

Courboulin A, Paulin R, Giguere N, Saksouk N, Perreault T, Meloche J . Role for miR-204 in human pulmonary arterial hypertension. J Exp Med. 2011; 208(3):535-48. PMC: 3058572. DOI: 10.1084/jem.20101812. View

Toshner M, Voswinckel R, Southwood M, Al-Lamki R, Howard L, Marchesan D . Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2009; 180(8):780-7. PMC: 2778151. DOI: 10.1164/rccm.200810-1662OC. View

Christman B, McPherson C, Newman J, King G, Bernard G, GROVES B . An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992; 327(2):70-5. DOI: 10.1056/NEJM199207093270202. View

10.

Fujiu K, Manabe I, Ishihara A, Oishi Y, Iwata H, Nishimura G . Synthetic retinoid Am80 suppresses smooth muscle phenotypic modulation and in-stent neointima formation by inhibiting KLF5. Circ Res. 2005; 97(11):1132-41. DOI: 10.1161/01.RES.0000190613.22565.13. View

11.

Rehman J, Archer S . A proposed mitochondrial-metabolic mechanism for initiation and maintenance of pulmonary arterial hypertension in fawn-hooded rats: the Warburg model of pulmonary arterial hypertension. Adv Exp Med Biol. 2010; 661:171-85. DOI: 10.1007/978-1-60761-500-2_11. View

12.

Darnell Jr J . STATs and gene regulation. Science. 1997; 277(5332):1630-5. DOI: 10.1126/science.277.5332.1630. View

13.

Csiszar A, Labinskyy N, Olson S, Pinto J, Gupte S, Wu J . Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension. 2009; 54(3):668-75. PMC: 2745434. DOI: 10.1161/HYPERTENSIONAHA.109.133397. View

14.

Bonnet S, Archer S, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R . A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007; 11(1):37-51. DOI: 10.1016/j.ccr.2006.10.020. View

15.

Bonnet S, Paulin R, Sutendra G, Dromparis P, Roy M, Watson K . Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation. 2009; 120(13):1231-40. DOI: 10.1161/CIRCULATIONAHA.109.848911. View

16.

Sehgal P, Mukhopadhyay S, Patel K, Xu F, Almodovar S, Tuder R . Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-nef-infected macaques. Am J Physiol Lung Cell Mol Physiol. 2009; 297(4):L729-37. PMC: 2770782. DOI: 10.1152/ajplung.00087.2009. View

17.

Wan H, Luo F, Wert S, Zhang L, Xu Y, Ikegami M . Kruppel-like factor 5 is required for perinatal lung morphogenesis and function. Development. 2008; 135(15):2563-72. PMC: 4459582. DOI: 10.1242/dev.021964. View

18.

Li B, Yang L, Shen J, Wang C, Jiang Z . The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phosphorylation. Anesth Analg. 2007; 105(4):1034-41, table of contents. DOI: 10.1213/01.ane.0000278736.81133.26. View

19.

Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R . The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther. 2008; 120(2):172-85. DOI: 10.1016/j.pharmthera.2008.08.002. View

20.

Grote K, Luchtefeld M, Schieffer B . JANUS under stress--role of JAK/STAT signaling pathway in vascular diseases. Vascul Pharmacol. 2005; 43(5):357-63. DOI: 10.1016/j.vph.2005.08.021. View